TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma

Biological Research

Volumn 48, Issue , 2015, Pages

  Chen, Yijie ^a   Ma, Lin ^b   He, Qian ^a   Zhang, Shaobo ^a   Zhang, Chenghua ^a   Jia, Wei ^c  

^a The 180th Hospital of People's Liberation Army   (China)

^b Eighth People's Hospital of Qingdao City   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Intrahepatic cholangiocarcinoma; Prognosis; Transforming growth factor beta 1 (TGF 1)

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR PROTEIN;

BILE DUCT CARCINOMA; BLOOD; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LIVER TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; TIME FACTOR;

BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84934922954     PISSN: 07169760     EISSN: 07176287     Source Type: Journal    
DOI: 10.1186/s40659-015-0016-9     Document Type: Article

References (22)

1. Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N, et al. Extended resections for hilar cholangiocarcinoma. Ann Surg. 1999;230:808-18.
2. Farley DR, Weaver AL, Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc. 2005;70:425-9.
3. Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma. Ann Surg. 2002;215:31-8.
4. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier- Hayes DJ. TGF-β1regulation of VEGF production by breast cancer cells. Ann Surg Oncol. 1997;4:621-7.
5. Huber MA, Kraut N, Beug H. Molecular requirements for epithelialmesenchymal transition during tumour progression. Curr Opin Cell Biol. 2005;17:548-58.
6. Jeon SH, Chae BC, Kim HA. Mechanisms underlying TGF-β1-induced expression of VEGF and Flk-1in mouse macrophages and their implications for angiogenesis. J Leukoc Biol. 2007;81:557-66.
7. Pepper MS. Transforming growth factor-β: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8:21-43.
8. Muraoka RS, Dumont N, Ritter CA. Blockade of TGF-β inhibits mammary tumour cell viability, migration, and metastases. J Clin Invest. 2002;109:1551-9.
9. Mitropoulos D, Kiroudi A, Christelli E, Serafetinidis E, Zervas A, Anastasiou I, et al. Expression of transforming growth factor beta in renal cell carcinoma and matched non-involved renal tissue. Urol Res. 2004;32:317-22.
10. Dong L, Ge XY, Wang YX, Yang LQ, Li SL, Yu GY, et al. Transforming growth factor-β and epithelial-mesenchymal transition are associated with pulmonary metastasis in adenoid cystic carcinoma. Oral Oncol. 2013;49:1051-8.
11. Reis ST, Pontes-Júnior J, Antunes AA, Sousa-Canavez JM, Abe DK, Cruz JA, et al. Tgf-β1 expression as a biomarker of poor prognosis in prostate cancer. Clinics (Sao Paulo). 2011;66:1143-7.
12. Von Rahden BH, Stein HJ, Feith M, Pühringer F, Theisen J, Siewert JR, et al. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. Mol Carcinog. 2006;45:786-94.
13. Fukai Y, Fukuchi M, Masuda N, Osawa H, Kato H, Nakajima T, et al. Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer. 2003;104:161-6.
14. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res. 2000;20:4489-93.
15. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996;110:375-82.
16. Patil AS, Sable RB, Kothari RM. An update on transforming growth factor-β (TGF-β): sources, types, functionsand clinical applicability for cartilage/bone healing. J Cell Physiol. 2011;226:3094-103.
17. Lin Y, Kikuchi S, Obata Y, Yagyu K. Tokyo Research Group on Prevention of Gastric Cancer. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol. 2006;21:432-7.
18. Krasagakis K, Thölke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer. 1998;77:1492-4.
19. Nakagohri T, Asano T, Kinoshita H, Kenmochi T, Urashima T, Miura F. Aggressive surgical resection for hilar-invasive and peripheral intrahepatic cholangiocarcinoma. World J Surg. 2013;27:289-93.
20. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology. 2013;37:961-9.
21. Sulkowski S, Wincewicz A, Sulkowska M, Koda M. Ann N Y Acad Sci. 2009;1171:116-23.
22. Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology. 2012;49:311-6.